A year and a half after landing a $23.5 million series A financing, Navitor Pharmaceuticals Inc. has attracted new investors to a $33 million series B round intended to help it identify a lead candidate in a pipeline of candidates capable of modulating the mammalian target of rapamycin complex 1 pathway and carrying it into the clinic by early 2018.